'Off-the-shelf'allogeneic CAR T cells: development and challenges
Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …
Exploiting innate immunity for cancer immunotherapy
M Yi, T Li, M Niu, Q Mei, B Zhao, Q Chu, Z Dai, K Wu - Molecular cancer, 2023 - Springer
Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …
However, most of these immunomodulatory strategies focus on harnessing adaptive …
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
A Heczey, AN Courtney, A Montalbano, S Robinson… - Nature medicine, 2020 - nature.com
Vα24-invariant natural killer T (NKT) cells have shown potent anti-tumor properties in murine
tumor models and have been linked to favorable outcomes in patients with cancer. However …
tumor models and have been linked to favorable outcomes in patients with cancer. However …
Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer
M Daher, K Rezvani - Cancer discovery, 2021 - AACR
Chimeric antigen receptor (CAR) engineering of T cells has revolutionized the field of
cellular therapy for the treatment of cancer. Despite this success, autologous CAR-T cells …
cellular therapy for the treatment of cancer. Despite this success, autologous CAR-T cells …
Challenges and new technologies in adoptive cell therapy
P Zhang, G Zhang, X Wan - Journal of Hematology & Oncology, 2023 - Springer
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma
D Martínez Bedoya, V Dutoit, D Migliorini - Frontiers in immunology, 2021 - frontiersin.org
Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the major
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …
Allogeneic CAR cell therapy—more than a pipe dream
KJ Caldwell, S Gottschalk, AC Talleur - Frontiers in immunology, 2021 - frontiersin.org
Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors
(CARs) has shown promise, particularly for the treatment of hematological malignancies. To …
(CARs) has shown promise, particularly for the treatment of hematological malignancies. To …
[HTML][HTML] Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy
Cell-based immunotherapy has become the new-generation cancer medicine, and" off-the-
shelf" cell products that can be manufactured at large scale and distributed readily to treat …
shelf" cell products that can be manufactured at large scale and distributed readily to treat …
The current landscape of NKT cell immunotherapy and the hills ahead
Simple Summary Natural killer T (NKT) cells are a subset of lipid-reactive T cells that
enhance anti-tumor immunity. While preclinical studies have shown NKT cell …
enhance anti-tumor immunity. While preclinical studies have shown NKT cell …
Mucosal-associated invariant T cells for cancer immunotherapy
YR Li, K Zhou, M Wilson, A Kramer, Y Zhu, N Dawson… - Molecular Therapy, 2023 - cell.com
Human mucosal-associated invariant T (MAIT) cells are characterized by their expression of
an invariant TCR α chain Vα7. 2-Jα33/Jα20/Jα12 paired with a restricted TCR β chain. MAIT …
an invariant TCR α chain Vα7. 2-Jα33/Jα20/Jα12 paired with a restricted TCR β chain. MAIT …